Please find enclosed the Audited Financial Statements for the quarter and financial year ended 31-03-2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sudarshan Pharma reported strong FY2026 results with standalone revenue from operations growing 32.8% to ₹6,675 crore from ₹5,025 crore in FY2025. Net profit after tax rose 56.8% to ₹2,198 lakh from ₹1,402 lakh, driven by higher trading volumes in chemicals and solvents. The company adopted Ind AS for the first time this year with a transition date of April 1, 2024. Despite the profit growth, operating cash flow turned negative at -₹275 lakh (vs -₹3,318 lakh in FY2025), reflecting a large buildup of inventories (up ₹6,961 lakh) and trade receivables (up ₹4,755 lakh). Total borrowings nearly doubled to ₹28,109 lakh, and the company completed acquisition of Srigen Lifesciences' API manufacturing facility in Telangana for ₹25.5 crore. The statutory auditor issued an unmodified (clean) opinion on the results.
Strong double-digit revenue and profit growth is positive for shareholders, but the negative operating cash flow and sharply higher debt levels raise concerns about working capital management and financial leverage. The stock may see mixed reaction.